Myles David C.

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
10
Insider Sells Sum
$951,877.08

Insider Activity of Myles David C.

According to the SEC Form 4 filings, Myles David C., being in a position of

  1. CH. DISCOV. & NON-CLIN DEV OFF at Olema Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 26066 shares for $234,916,
    over all time since 2021-12-10, has bought 0 shares, and sold 80436 shares for $951,877.

The largest sale of all time was on 2023-09-19 and amounted to 20000 shares of Olema Pharmaceuticals, Inc. for $253,400.

Biography of Myles David C.

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$234,9162100

Comparison of Insiders on Amount of Buys and Sells

2024-12-11SaleOlema Pharmaceuticals, Inc.
OLMA
CH. DISCOV. & NON-CLIN DEV OFF
13,614
0.0247%
$8.68$118,116-34.6%
2024-12-10SaleOlema Pharmaceuticals, Inc.
OLMA
CH. DISCOV. & NON-CLIN DEV OFF
12,452
0.0218%
$9.38$116,800-42.84%
2023-11-22SaleOlema Pharmaceuticals, Inc.
OLMA
CH. DISCOV. & NON-CLIN DEV OFF
6,653
0.0123%
$13.89$92,410-13.42%
2023-11-21SaleOlema Pharmaceuticals, Inc.
OLMA
CH. DISCOV. & NON-CLIN DEV OFF
6,976
0.0134%
$14.88$103,823-16.06%
2023-11-08SaleOlema Pharmaceuticals, Inc.
OLMA
CH. DISCOV. & NON-CLIN DEV OFF
200
0.0004%
$17.61$3,522-29.67%
2023-11-03SaleOlema Pharmaceuticals, Inc.
OLMA
CH. DISCOV. & NON-CLIN DEV OFF
541
0.001%
$17.51$9,473-27.31%
2023-11-02SaleOlema Pharmaceuticals, Inc.
OLMA
CH. DISCOV. & NON-CLIN DEV OFF
3,332
0.006%
$15.36$51,180-23.32%
2023-11-01SaleOlema Pharmaceuticals, Inc.
OLMA
CH. DISCOV. & NON-CLIN DEV OFF
6,668
0.0122%
$15.02$100,153-19.01%
2023-09-19SaleOlema Pharmaceuticals, Inc.
OLMA
CH. DISCOV. & NON-CLIN DEV OFF
20,000
0.0367%
$12.67$253,400-3.13%
2021-12-10SaleOlema Pharmaceuticals, Inc.
OLMA
10,000
0.0254%
$10.30$103,000-60.27%
Total: 10
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.